Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01925560 · ClinicalTrials.gov registry record · NA

Tolerance and Utilization of Agave Inulin in Healthy Adults

A NA study of Tolerance, sponsored by University of Illinois at Urbana-Champaign.

Completed
Registry status
NA
Development phase
30
Enrollment target
1
Study location

NCT01925560: Completed NA study of Tolerance, sponsored by University of Illinois at Urbana-Champaign.

NCT01925560 is a NA study of Tolerance that has completed, run by University of Illinois at Urbana-Champaign. The registered enrollment target is 30 participants, below the 51-participant average among 7 other Tolerance trials with a reported enrollment target (41% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01925560, a NA study of Tolerance, has completed, sponsored by University of Illinois at Urbana-Champaign.

COMPLETED
Registry status
NA
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

The objective of this study is to assess the tolerance and utilization of agave inulin. This will be accomplished through analyses of breath and fecal samples to quantify fermentation end-products- hydrogen, carbon dioxide, and methane will be measured in the breath, and short-chain fatty acids, ammonia, phenol, and indole will be measured in feces. Microbial populations will also be measured in fecal samples.

Primary Outcome

On the 21st day of each treatment period, participants will come into the laboratory after an overnight (12 hour) fast and begin breath gas testing. The baseline breath gas sample will occur upon arrive. Breath gas collection will utilize the Quintron EasySampler and tubes. Participants will blow into the EasySampler for 1-2 seconds while inserting a tube into a needle holder that allows the collection of the breath gas. After the baseline sample, the participants will consume their respective t

Conditions Studied

Interventions

  • OTHER Placebo
  • OTHER Agave Inulin

Study Locations (1)

Illinois

  • University of Illinois - Urbana

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2013-01
Est. Completion 2014-05
Phase NA

What the finished NCT01925560 record still lists

NCT01925560 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 51-participant average among 7 other Tolerance trials with a reported enrollment target (41% lower).

The record links to 1 condition, with Tolerance appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT01925560 reports a single indexed study location in Illinois.

Frequently Asked Questions

What is clinical trial NCT01925560 about?

NCT01925560 is a clinical study titled "Tolerance and Utilization of Agave Inulin in Healthy Adults". The objective of this study is to assess the tolerance and utilization of agave inulin. This will be accomplished through analyses of breath and fecal samples to quantify fermentation end-products- hydrogen, carbon dioxide, and methane will be measured in the breath, and short-chain fatty acids, amm...

What is the current status of trial NCT01925560?

This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2013-01. Estimated completion is 2014-05.

What conditions does trial NCT01925560 study?

This clinical trial studies the following conditions: Tolerance.

What interventions are being tested in trial NCT01925560?

The interventions under investigation include: Placebo (OTHER), Agave Inulin (OTHER).

Who is sponsoring clinical trial NCT01925560?

This trial is sponsored by University of Illinois at Urbana-Champaign, which has 129 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01925560 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Tolerance

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01925560, the US trial registry maintained by the National Library of Medicine. NCT01925560 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.